Evidence map›Paper›PMID 40969883›Full record

ArticleACS pharmacology & translational science2025

Bioglass/Ceria Nanoparticle Hybrids for the Prophylactic Treatment of Seroma: A Comparative Short-Term Study in Rats.

Michael-Alexander Pais, Simone de Brot, Robert Nißler, Isabel Arenas Hoyos, Athanasios Papanikolaou, Davide Bottone, Alexander Gogos, Anja Helmer, Robert Rieben, Mihai Constantinescu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Michael-Alexander PaisDepartment of Plastic and Hand Surgery, Inselspital, University Hospital Bern, Bern 3010, Switzerland.ORCID https://orcid.org/0009-0002-2826-0472
Simone de BrotCOMPATH, Institute of Animal Pathology, University of Bern, Bern 3012, Switzerland.
Robert NißlerDepartment of Materials Meet Life, Swiss Federal Laboratories for Materials Science and Technology (Empa), St. Gallen 9014, Switzerland.
Isabel Arenas HoyosDepartment of Plastic and Hand Surgery, Inselspital, University Hospital Bern, Bern 3010, Switzerland.
Athanasios PapanikolaouDepartment of Plastic and Hand Surgery, Inselspital, University Hospital Bern, Bern 3010, Switzerland.
Davide BottoneDepartment of Materials Meet Life, Swiss Federal Laboratories for Materials Science and Technology (Empa), St. Gallen 9014, Switzerland.
Alexander GogosDepartment of Materials Meet Life, Swiss Federal Laboratories for Materials Science and Technology (Empa), St. Gallen 9014, Switzerland.
Anja HelmerDepartment for BioMedical Research, University of Bern, Bern 3008, Switzerland.
Robert RiebenDepartment for BioMedical Research, University of Bern, Bern 3008, Switzerland.
Mihai ConstantinescuDepartment of Plastic and Hand Surgery, Inselspital, University Hospital Bern, Bern 3010, Switzerland.
Tino MatterDepartment of Materials Meet Life, Swiss Federal Laboratories for Materials Science and Technology (Empa), St. Gallen 9014, Switzerland.
Inge HerrmannDepartment of Materials Meet Life, Swiss Federal Laboratories for Materials Science and Technology (Empa), St. Gallen 9014, Switzerland.
Ioana LeseDepartment of Plastic and Hand Surgery, Inselspital, University Hospital Bern, Bern 3010, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Seroma formation remains a common postoperative complication. While optimal treatment remains unclear, recent attention has turned to bioglass/ceria nanoparticle (NP) treatment for seromas. Previous work showed complete seroma resolution in a rat model after NP treatment in the long term. This study aimed to assess the short-term prophylactic effects of NPs. Twenty male Lewis rats underwent bilateral seroma induction surgery. Postoperatively, seroma cavities were treated with NPs, vehicle buffer solution, or fibrin glue or left untreated. Over 2 weeks, blood, seroma fluid, and tissues were collected for biochemical, histopathological, and immunohistochemical analyses. By day 14, NP-treated seromas showed 100% fluid resolution. In contrast, seromas persisted in 50% of fibrin glue-treated rats, 60% of vehicle-treated rats, and 44.44% of untreated controls. Furthermore, prophylactic NP treatment resulted in decreased levels of inflammatory markers while the effect of fibrin glue was to increase the pro-inflammatory response. Histologically, a reduction in vascularization and individual macrophage infiltration was observed in seroma superficial capsules after NP treatment, while complement proteins were significantly increased and associated with groups of macrophages that colocalized with NPs. At the end point, NPs did not show any biodistribution to the systemic circulation. Prophylactic NP application reduced early seroma manifestations mostly through their anti-inflammatory effects. Members of the complement cascade were also identified in macrophages that colocalized with NPs and were internalized. Moreover, there were no detectable adverse systemic effects. These findings emphasize the clinical potential of NPs in the prevention of seromas and their potential for clinical use.

Indexed as

animal rat modelbioglass/ceria nanoparticle hybridscomplement protein activationmacrophage infiltration and colocalization with nanoparticlesseroma formation

Identifiers

PMID40969883
PMCPMC12441835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.